Ipsen Reports Reduced Migraine Days With Dysport In Phase 3 BEOND Topline Data

Ipsen S.A. (IPN.PA), a biopharmaceutical company, on Thursday reported positive topline results in the Phase 3 BEOND study for Dysport, a botulinum-derived drug developed for treating episodic and chronic migraines.